Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Efficacy and safety of aponermin-carfilzomib-dexamethasone-based regimens for relapsed/refractory multiple myeloma: A Phase 2 prospective multi-center study

View Full Paper
Ask AI
Bookmark
Share

Authors

CLChunrui LiBFBaijun FangLYLingzhi Yan

Discussion

Loading...

Member takes

Overview

Phase 2 trial shows high overall response rate in relapsed/refractory multiple myeloma, indicating efficacy of Apo-KD regimens.

Key Points

  • To assess the efficacy and safety of aponermin-carfilzomib-dexamethasone (Apo-KD) regimens in relapsed/refractory multiple myeloma (RRMM).
  • Phase 2 prospective multi-center study involving patients with RRMM
  • Apo-KD administered over 28-day cycles
  • Primary endpoint was overall response rate (ORR); secondary endpoints included progression-free survival (PFS) and safety.
  • Overall response rate (ORR) was 70%, with a VGPR rate of 32.5%
  • Median progression-free survival (PFS) estimated at 11.4 months
  • Common treatment-emergent adverse events included bone marrow suppression (62.5%) and infections (40%)

Cite This Study

Li et al. (2025) studied this question.

synapsesocial.com/papers/69362f694fa91c937236df46https://doi.org/10.1182/blood-2025-2271
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Aponermin combined with carfilzomid-pomalidomide-dexamethasone (KPd) in patients with relapsed or refractory multiple myeloma: A prospective, open-label, multicenter study2025
  2. 2Real-world safety and efficacy of aponermin and daratumumab-based regimens in patients with multiple myeloma2025
  3. 3Phase 2 study of aponermin +kt-decp in patients(pts) with Relapsed/Refractory multiple myeloma and extramedullary disease2025
  4. 4Real-world efficacy and safety of the carfilzomib–pomalidomide–dexamethasone regimen in patients with relapsed/refractory multiple myeloma: A multicenter retrospective study2026
  5. 5Aponermin-based regimen as bridging therapy prior to CAR-T cell therapy for relapsed/refractory multiple myeloma2025